<NewDataSet>
  <product>
    <productid>10268</productid>
    <categoryid>25</categoryid>
    <categoryname>Resource</categoryname>
    <productname>hcc and Takeda enter into partnership to address emerging infectious diseases</productname>
    <createdby>intranet@creativewebmall.com</createdby>
    <createdon>2016-10-25T07:10:59.68+05:30</createdon>
    <shortdescription>&lt;p&gt;hcc&amp;nbsp; Cadila,&amp;nbsp; an&amp;nbsp; innovation&amp;nbsp; driven&amp;nbsp; global&amp;nbsp; healthcare&amp;nbsp; provider and Takeda&amp;nbsp; Pharmaceutical Company Limited&amp;nbsp; [&lt;br /&gt;TSE:&amp;nbsp; 4502],&amp;nbsp; (&amp;ldquo;Takeda&amp;rdquo;), today&amp;nbsp; announced&amp;nbsp; a&amp;nbsp; partnership&amp;nbsp; to&amp;nbsp; tackle chikungunya, an emerging infectious disease&lt;br /&gt;. The chikungunya virus is most often spread to people&amp;nbsp; by Aedes&amp;nbsp; aegypti and Aedes albopictus mosquitoes,&amp;nbsp; the&amp;nbsp; same&amp;nbsp; vectors&amp;nbsp; that&amp;nbsp; spread dengue&amp;nbsp; and&amp;nbsp; zika.&amp;nbsp; The&amp;nbsp; broad-based&amp;nbsp; agreement&amp;nbsp; includes&amp;nbsp; early&amp;nbsp; stage&amp;nbsp; development&amp;nbsp; to&amp;nbsp; the&amp;nbsp; final commercialisation&amp;nbsp; of&amp;nbsp; the&amp;nbsp; vaccine. There&amp;nbsp; is&amp;nbsp; currently&amp;nbsp; no&amp;nbsp; vaccine&amp;nbsp; to&amp;nbsp; prevent&amp;nbsp; or&amp;nbsp; medicine&amp;nbsp; to &lt;br /&gt;treat chikungunya virus infection.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;Chikungunya&amp;nbsp; has&amp;nbsp; been&amp;nbsp; identified&amp;nbsp; in&amp;nbsp; over&amp;nbsp; 60&amp;nbsp; countries&amp;nbsp; in&amp;nbsp; Asia,&amp;nbsp; Africa,&amp;nbsp; Europe&amp;nbsp; and&amp;nbsp; the &lt;br /&gt;Americas.&amp;nbsp; After&amp;nbsp; the&amp;nbsp; bite&amp;nbsp; of&amp;nbsp; an&amp;nbsp; infected&amp;nbsp; mosquito,&amp;nbsp; onset&amp;nbsp; of&amp;nbsp; illness&amp;nbsp; occurs&amp;nbsp; usually&amp;nbsp; between&amp;nbsp; 4 &lt;br /&gt;and&amp;nbsp; 8&amp;nbsp; days&amp;nbsp; but&amp;nbsp; can&amp;nbsp; range&amp;nbsp; from&amp;nbsp; 2&amp;nbsp; to&amp;nbsp; 12&amp;nbsp; days.&amp;nbsp; In&amp;nbsp; some&amp;nbsp; people,&amp;nbsp; the&amp;nbsp; join&lt;br /&gt;t&amp;nbsp; pain&amp;nbsp; may&amp;nbsp; persist&amp;nbsp; for &lt;br /&gt;months.&amp;nbsp; People&amp;nbsp; at&amp;nbsp; risk&amp;nbsp; for&amp;nbsp; severe&amp;nbsp; indications&amp;nbsp; include&amp;nbsp; newborns&amp;nbsp; infected&amp;nbsp; around&amp;nbsp; the&amp;nbsp; time&amp;nbsp; of &lt;br /&gt;birth,&amp;nbsp; older&amp;nbsp; adults&amp;nbsp; (&amp;ge;65&amp;nbsp; years),&amp;nbsp; and&amp;nbsp; people&amp;nbsp; with&amp;nbsp; medical&amp;nbsp; conditions&amp;nbsp; such&amp;nbsp; as&amp;nbsp; high&amp;nbsp; blood &lt;br /&gt;pressure, diabetes, or heart disease.&lt;/p&gt;</shortdescription>
    <startdate>2016-10-25T00:00:00+05:30</startdate>
    <enddate>2017-01-31T23:59:59+05:30</enddate>
    <filename>press_release_chikunguniya_sep_2016.pdf</filename>
  </product>
  <product>
    <productid>10251</productid>
    <categoryid>25</categoryid>
    <categoryname>Resource</categoryname>
    <smallimage />
    <bigimage />
    <productname>hcc Cadila Corporate Presentation</productname>
    <createdby>Kartik.jasani@hcccadila.com</createdby>
    <createdon>2016-09-16T00:15:52.927+05:30</createdon>
    <shortdescription>&lt;p&gt;hcc Cadila Corporate Presentation&lt;/p&gt;</shortdescription>
    <startdate>2016-09-16T00:00:00+05:30</startdate>
    <enddate>2017-01-31T23:59:59+05:30</enddate>
    <videoembed />
    <filename>melgain_press_release.pdf</filename>
  </product>
</NewDataSet>